CONMED (NYSE:CNMD) Issues FY 2025 Earnings Guidance

CONMED (NYSE:CNMD) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.250-4.400 for the period, compared to the consensus estimate of 4.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Analyst Upgrades and Downgrades

Several research analysts have commented on CNMD shares. StockNews.com lowered shares of CONMED from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 target price on shares of CONMED in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $79.80.

CONMED Stock Performance

Shares of CNMD stock traded up $1.47 on Wednesday, hitting $74.35. The company had a trading volume of 573,352 shares, compared to its average volume of 415,094. The company has a quick ratio of 1.06, a current ratio of 2.27 and a debt-to-equity ratio of 1.01. The firm has a market cap of $2.30 billion, a P/E ratio of 17.66, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46. The company has a 50-day moving average price of $70.62 and a 200-day moving average price of $70.19. CONMED has a twelve month low of $61.05 and a twelve month high of $88.60.

CONMED (NYSE:CNMD) last issued its earnings results on Wednesday, February 5th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.14. CONMED had a return on equity of 13.84% and a net margin of 10.23%. As a group, equities research analysts predict that CONMED will post 4.03 earnings per share for the current fiscal year.

CONMED Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were issued a $0.20 dividend. The ex-dividend date was Friday, December 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.08%. CONMED’s dividend payout ratio (DPR) is presently 19.00%.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.